 "Unichem gets USFDA nod for generic version of tolterodine tartrate tablets")
Unichem Laboratories Ltd on Thursday said it has received approval from the US health regulator to market its generic version of tolterodine tartrate tablets used in the treatment of overactive urinary bladder.
The approval by the US Food and Drug Administration (USFDA) to market tolterodine tartrate tablets is for strengths of 1 mg and 2 mg, Unichem Laboratories said in a regulatory filing.
The tolterodine tartrate tablets are generic versions of Pfizer Inc's DETROL tablets, it added.
The tablets are indicated for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
The product will be commercialised from Unichem's Goa plant, the company said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app